Log in

VolitionRX Stock Price, News & Analysis (NYSEAMERICAN:VNRX)

$5.68
+0.25 (+4.60 %)
(As of 10/21/2019 06:10 AM ET)
Today's Range
$5.42
Now: $5.68
$5.80
50-Day Range N/A
52-Week Range
$1.67
Now: $5.68
$6.84
Volume185,581 shs
Average Volume136,157 shs
Market Capitalization$233.39 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:VNRX
Previous SymbolNYSEMKT:VNRX
CUSIPN/A
CIKN/A
Phone646 650 1351

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees44
Market Cap$233.39 million
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable

Receive VNRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.


VolitionRX (NYSEAMERICAN:VNRX) Frequently Asked Questions

What is VolitionRX's stock symbol?

VolitionRX trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."

How were VolitionRX's earnings last quarter?

VolitionRX Ltd (NYSEAMERICAN:VNRX) released its earnings results on Monday, August, 12th. The medical research company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.01. View VolitionRX's Earnings History.

When is VolitionRX's next earnings date?

VolitionRX is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for VolitionRX.

What price target have analysts set for VNRX?

2 analysts have issued 1-year target prices for VolitionRX's shares. Their forecasts range from $5.00 to $6.00. On average, they expect VolitionRX's stock price to reach $5.50 in the next year. This suggests that the stock has a possible downside of 3.2%. View Analyst Price Targets for VolitionRX.

What is the consensus analysts' recommendation for VolitionRX?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRX in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VolitionRX.

Has VolitionRX been receiving favorable news coverage?

Press coverage about VNRX stock has been trending somewhat positive this week, according to InfoTrie. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. VolitionRX earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for VolitionRX.

Are investors shorting VolitionRX?

VolitionRX saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 308,200 shares, an increase of 390.0% from the August 30th total of 62,900 shares. Based on an average daily volume of 237,300 shares, the days-to-cover ratio is presently 1.3 days. Approximately 1.3% of the company's shares are sold short. View VolitionRX's Current Options Chain.

Who are some of VolitionRX's key competitors?

What other stocks do shareholders of VolitionRX own?

Who are VolitionRX's key executives?

VolitionRX's management team includes the folowing people:
  • Dr. Martin Charles Faulkes, Exec. Chairman (Age 75)
  • Mr. Cameron Reynolds, Founder, CEO, Pres & Director (Age 48)
  • Dr. Jacob Vincent Micallef Ph.D., MBA, Chief Scientific Officer (Age 63)
  • Dr. Jason Bradley Terrell, Chief Medical Officer (Age 39)
  • Mr. Rodney Gerard Rootsaert LLB, Corp. Sec. (Age 48)

How do I buy shares of VolitionRX?

Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is VolitionRX's stock price today?

One share of VNRX stock can currently be purchased for approximately $5.68.

How big of a company is VolitionRX?

VolitionRX has a market capitalization of $233.39 million. VolitionRX employs 44 workers across the globe.View Additional Information About VolitionRX.

What is VolitionRX's official website?

The official website for VolitionRX is http://www.volitionrx.com/.

How can I contact VolitionRX?

The medical research company can be reached via phone at 646 650 1351.


MarketBeat Community Rating for VolitionRX (NYSEAMERICAN VNRX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  170 (Vote Outperform)
Underperform Votes:  141 (Vote Underperform)
Total Votes:  311
MarketBeat's community ratings are surveys of what our community members think about VolitionRX and other stocks. Vote "Outperform" if you believe VNRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel